Mega Genomics Limited reported that as of 28 February 2026, total authorised share capital stood at USD 50,000, comprising 500.00 million authorised ordinary shares at a par value of USD 0.0001 each. The data showed that 224.30 million shares were issued, with no treasury shares, indicating no changes in issued share capital compared to the preceding month.

The disclosure also confirmed compliance with the mandatory public float requirement at the 25% threshold. No other share-related agreements or arrangements were reported during the month, and no changes were noted in warrants or convertible securities.